Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations.

Guideline ID: 3509 Published: 2024 Jan 15

American Thoracic Society (ATS)

Raghu G, Montesi SB, Silver RM, et al. Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2024 Jan 15;209(2):137-152. [55 references] PubMed

View Original Guideline

Overview

Guideline Objective

To provide evidence-based treatment recommendations for patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)

Patient Population

Patients with SSc-ILD

Recommendations

Recommendation Statements

Major interventions covered in this guideline include:

- Guidance on use of pharmacological treatment (cyclophosphamide, mycophenolate, rituximab, tocilizumab, nintedanib, pirfenidone), including combination therapy

Note: Full recommendation statements have not been provided because this guideline does not meet EGT's systematic review of the evidence criteria. Refer to the original guideline for more information.

Evidence Rating Scheme

Refer to the original guideline documentation for more information.

Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

Related Content

Supporting Documents

- Appendix.
- Cyclophosphamide in Patients with Systemic Sclerosis–associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis; 2023 Aug 1.
- Mycophenolate in Patients with Systemic Sclerosis–associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis; 2023 Apr 7.
- Rituximab in Patients with Systemic Sclerosis–associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis; 2023 Jul 17.
- Tocilizumab in Patients with Systemic Sclerosis–associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis; 2023 Sep 7.
- Nintedanib Therapy Alone and Combined with Mycophenolate in Patients with Systemic Sclerosis–associated Interstitial Lung Disease: Systematic Reviews and

Meta-Analysis; 2023 Jul 18.

- An Official ATS Statement: Grading the Quality of Evidence and Strength of Recommendations in ATS Guidelines and Recommendations; 2006.
- American Thoracic Society Clinical Practice Guideline Development Manual; 2020 May.
- American Thoracic Society Guidelines Packet; 2023 Apr.

Implementation Tools

- Summary for Clinicians; 2024 Jan.
- Continuing Medical Education; 2023 Dec 29.
- The Original Guideline includes the following:
    - Figure 1. Summary of Treatment Recommendations for Patients with SSc-ILD (p. 149)

Patient Education

No patient education materials available.

Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.

Copyright © 2025 ECRI